Investors

Press Releases

All Releases

View Summary NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab
Feb 18, 2015
PDF 20.6 KB Add to Briefcase
View Summary New Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels
Feb 18, 2015
PDF 22.5 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2015 Investor Conference Presentations
Feb 13, 2015
PDF 7.8 KB Add to Briefcase
View Summary Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
Feb 10, 2015
PDF 41.2 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Jan 26, 2015
PDF 15.8 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
Jan 23, 2015
PDF 16.0 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA
Jan 12, 2015
PDF 15.6 KB Add to Briefcase
View Summary Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015
Jan 9, 2015
PDF 8.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia
Jan 9, 2015
PDF 18.1 KB Add to Briefcase
View Summary Regeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference
Dec 19, 2014
PDF 8.5 KB Add to Briefcase
View Summary Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol
Dec 15, 2014
PDF 171.9 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Dec 1, 2014
PDF 16.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Nov 20, 2014
PDF 17.4 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
Nov 19, 2014
PDF 22.7 KB Add to Briefcase
View Summary Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
Nov 18, 2014
PDF 15.2 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
Nov 11, 2014
PDF 18.4 KB Add to Briefcase
View Summary Regeneron Reports Third Quarter 2014 Financial and Operating Results
Nov 4, 2014
PDF 40.3 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2014 Investor Conference Presentations
Nov 3, 2014
PDF 6.9 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Oct 20, 2014
PDF 17.0 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Oct 17, 2014
PDF 16.2 KB Add to Briefcase
Showing 21-40 of 282 Page: 1 2 3 4 5 6 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)